The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid sustained analyst optimism within the insurance sector, TD Cowen analyst Andrew Kligerman raised the price target for Globe Life from $199 to $215 while maintaining a Buy rating. The new target implies a projected upside of 8.04% from current market levels. The company achieved a notable GF Score of 85/100, driven by robust growth and momentum, even as reports highlighted recent insider sales totaling $30.1 million.
Sign in to access this content
Sign InThis bullish adjustment follows a strong performance in early 2024, where Globe Life reported a 25% increase in Q1 net income to $2.78 per diluted share, according to company filings. When compared to industry peers like MetLife, which has also shown resilient earnings, GL continues to demonstrate superior operational momentum. Market data suggests that the company's fundamental strength is currently outweighing valuation concerns raised by some technical metrics.
Globe Life (GL) shares stood at $170.76 at the close of June 18, 2026, fluctuating between a high of $172.74 and a low of $169.55 during that session. Investors should monitor the $169.50 support level as a key indicator for continued upward momentum toward the $215 target. Upcoming catalysts include the broader impact of recent Fed interest rate decisions, which remain a critical driver for the investment portfolios of life insurance providers.